Last reviewed · How we verify
NCT04965623: AlT-FloW
ExplorATory Study oF the EdWards Transcatheter Atrial Shunt System (AlT FloW Germany)
NA trial testing Atrial Shunt in Heart Failure. Withdrawn.
6 December 2023
Quick facts
| Lead sponsor | Edwards Lifesciences |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 22 February 2021 |
| Primary completion | 6 December 2023 |
| Estimated completion | 6 December 2023 |
Drugs / interventions tested
- Atrial Shunt
Conditions studied
- Heart Failure — all drugs for Heart Failure →
Sponsor
Edwards Lifesciences — full company profile →
Who can join
18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Exploratory Study of the Edwards Transcatheter Atrial Shunt System is a multi-center, prospective, exploratory study to evaluate initial clinical safety, device functionality, and effectiveness of the Edwards Transcatheter Atrial Shunt System.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back.
Parra-Lucares A, Romero-Hernández E, Villa E, Weitz-Muñoz S, et al · · 2022 · cited 1× · PMID 36672578 · DOI 10.3390/biomedicines11010070
Verify or expand the search:
- PubMed search for NCT04965623
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other Edwards Lifesciences trials
Trials by the same sponsor.
- NCT07317648 — ClearSight NextGen1 Study · NA · completed
- NCT06833476 — TTVR STRONG Under Coverage With Evidence Development (CED) Study · recruiting
- NCT06569602 — Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU) · recruiting
- NCT06834516 — ClearSight Baby Cuff · completed
- NCT05957406 — SMART TRENDS Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04965623 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Edwards Lifesciences
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04965623.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing